A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Boys with Duchenne Muscular Dystrophy
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Ambulatory Boys With Duchenne Muscular Dystrophy
Category & Conditions: Rare Diseases
Medicine: Domagrozumab (PF-06252616)
ClinicalTrials.gov Identifier (NCT): NCT02310763
Protocol ID: B5161002
PrintDownloadOpen Plain Language Summary Result: Click here